International Urogynecology Journal

, Volume 22, Issue 4, pp 401–405 | Cite as

Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis

  • Paul F. Engelhardt
  • Nike Morakis
  • Lukas K. Daha
  • Britta Esterbauer
  • Claus R. Riedl
Original Article

Abstract

Introduction and hypothesis

While the short-term efficacy of intravesical hyaluronan for bladder pain syndrome/interstitial cystitis (BPS/IC) has been demonstrated, no data exist on the long-term outcome of this therapy.

Methods

Seventy BPS/IC patients treated with intravesical hyaluronan therapy from 2001 to 2003 were asked to rate their present status of bladder symptoms on a visual analog scale.

Results

Forty-eight of 70 patients responded after a mean follow-up of 4.9 years. The average initial VAS score of 8.15 had been reduced to 2.71 after therapy and further to 2.14 5 years later. Fifty percent of patients (24/48) reported complete bladder symptom remission at 5 years follow-up without any additional therapy; 41.7% (20/48) with symptom recurrence was improved with hyaluronan maintenance therapy. No improvement was reported by four patients.

Conclusions

Besides a high rate of acute symptom remission, intravesical hyaluronan also shows long-term efficacy in a considerable number of BPS/IC patients.

Keywords

Bladder pain syndrome GAG substitution Hyaluronan Hyaluronic acid Instillation therapy Interstitial cystitis 

Notes

Conflicts of interest

Claus R. Riedl is the principal investigator for controlled study on Hyaluronan in BPS/IC (CISTIC).

References

  1. 1.
    Toft BR, Nordling J (2006) Recent developments of intravesical therapy of painful bladder syndrome/interstitial cystitis: a review. Curr Opin Urol 16:268–272PubMedCrossRefGoogle Scholar
  2. 2.
    Morales A, Emerson L, Nickel JC, Lundie M (1996) Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J Urol 156:45–48PubMedCrossRefGoogle Scholar
  3. 3.
    Fall M, Oberpenning F, Peeker R (2008) Treatment of bladder pain syndrome/interstitial cystitis 2008: can we make evidence-based decisions? Eur Urol 54:65–78PubMedCrossRefGoogle Scholar
  4. 4.
    Porru D, Campus G, Tudino D, Valdes E, Vespa A, Scarpa RM, Usai E (1997) Results of treatment of refractory interstitial cystitis with intravesical hyaluronic acid. Urol Int 59:26–29PubMedCrossRefGoogle Scholar
  5. 5.
    Bade JJ, Laseur M, Nieuwenburg A, van der Weele LT, Mensink HJ (1997) A placebo controlled study of intravesical pentosanpolysulfate for the treatment of interstitial cystitis. Br J Urol 79:168–171PubMedGoogle Scholar
  6. 6.
    Parsons CL, Housley T, Schmidt JD, Lebow D (1994) Treatment of interstitial cystitis with intravesical heparin. Br J Urol 73:504–507PubMedCrossRefGoogle Scholar
  7. 7.
    Steinhoff G, Ittah B, Rowan S (2002) The efficacy of chondroitin sulfate 0.2% in treating interstitial cystitis. Can J Urol 9:1454–1458PubMedGoogle Scholar
  8. 8.
    Nickel JC, Egerdie B, Downey J, Singh R, Skehan A, Carr L, Irvine-Bird K (2009) A real-life multicentre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis. BJU Int 103(1):56–60PubMedCrossRefGoogle Scholar
  9. 9.
    Riedl CR, Engelhardt PF, Daha KL, Morakis N, Pflüger H (2008) Hyaluronan treatment of interstitial cystitis/painful bladder syndrome. Int Urogyneocol J Pelvic Floor Dysfunct 19(5):717–721CrossRefGoogle Scholar
  10. 10.
    Kallestrup EB, Steinunn S, Jørgense S, Nordling J, Hald T (2005) Treatment of interstitial cystitis with Cystistat®: a hyaluronic acid product. Scand J Urol Nephrol 39:143–147PubMedCrossRefGoogle Scholar
  11. 11.
    Daha LK, Riedl CR, Hohlbrugger G, Knoll M, Engelhardt PF, Pfluger H (2003) Comparative assessment of maximal bladder capacity, 0.9% NaCL versus 0.2M KCl, for the diagnosis of interstitial cystitis: a prospective controlled study. J Urol 170:807–809PubMedCrossRefGoogle Scholar
  12. 12.
    Hurst RE (1994) Structure, function, and pathology of proteoglycans and glycosaminoglycans in the urinary tract. World J Urol 12:3–10PubMedCrossRefGoogle Scholar
  13. 13.
    Leppilahti M, Hellström P, Tammela TLJ (2002) Effect of diagnostic hydrodistension and four intravesical Hyaluronan Instillations on bladder ICAM-1 intensity and association of ICAM-1 intensity with clinical response in patients with interstitial cystitis. Urology 60:46–51PubMedCrossRefGoogle Scholar
  14. 14.
    Schulz A, Vestweber AM, Dressler D (2009) Anti-inflammatory action of a hyaluronic acid-chondroitin sulphate preparation in an in vitro bladder model. Akt Urol 40(2):109–112CrossRefGoogle Scholar
  15. 15.
    Parsons CL, Forrest J, CJ CJ, the Elmiron Study Group (2002) Effect of pentosan polysulfate therapy on intravesical potassium sensitivity. Urology 59:329–334PubMedCrossRefGoogle Scholar
  16. 16.
    Gupta SK, Pidcock L, Parr NJ (2005) The potassium sensitivity test: a predictor of treatment response in interstitial cystitis. BJU Int 96:1063–1066PubMedCrossRefGoogle Scholar
  17. 17.
    Teichman JM, Nielsen-Omeis BJ (1999) Potassium leak test predicts outcome in interstitial cystitis. J Urol 161:1791–1796PubMedCrossRefGoogle Scholar
  18. 18.
    Daha L, Riedl CR, Lazar D, Simak R, Pflüger H (2008) Effect of intravesical glycosaminoglycan substitution therapy on bladder pain syndrome/interstitial cystitis, bladder capacity and potassium sensitivity. Scand J Urol 42(4):369–372CrossRefGoogle Scholar

Copyright information

© The International Urogynecological Association 2010

Authors and Affiliations

  • Paul F. Engelhardt
    • 1
  • Nike Morakis
    • 1
  • Lukas K. Daha
    • 2
  • Britta Esterbauer
    • 3
  • Claus R. Riedl
    • 1
  1. 1.Department of UrologyLandesklinikum Thermenregion BadenBadenAustria
  2. 2.Department of UrologyKrankenhaus HietzingViennaAustria
  3. 3.Urologic ClinicParacelsus University of MedicineSalzburgAustria

Personalised recommendations